Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.

Alcohol use disorder Digital health Digital therapeutics Mobile health Smoking Substance use disorder Technology Telehealth

Journal

The Psychiatric clinics of North America
ISSN: 1558-3147
Titre abrégé: Psychiatr Clin North Am
Pays: United States
ID NLM: 7708110

Informations de publication

Date de publication:
09 2022
Historique:
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

The US opioid crisis and the COVID-19 pandemic have sparked innovation in substance use disorder (SUD) treatment such that telehealth, remote monitoring, and digital health interventions are increasingly feasible and effective. These technologies can increase SUD treatment access and acceptability, even for nontreatment seeking, remote, and underserved populations, and can be used to reduce health disparities. Overall, digital tools will likely overcome many barriers to delivery of evidence-based behavioral treatments such as cognitive behavioral therapy and contingency management, that, along with appropriate medications, constitute the foundation of treatment of SUDs.

Identifiants

pubmed: 36055736
pii: S0193-953X(22)00048-X
doi: 10.1016/j.psc.2022.05.006
pmc: PMC9352538
pii:
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-528

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure This work was funded by the NIH/NIAAA Small Business Innovative Research and Small Business Technology Transfer Grants R43AA026234, R44AA026234, and R44DA055396. The funding source was not involved in the study design, research, or the preparation of the article. Dr M.M. Sweeney is now employed by the National Institutes of Health, National Institute of Mental Health. This article was prepared while Dr M.M. Sweeney was employed at Johns Hopkins University. The opinions expressed in this article are the authors’ own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government. Dr M.M. Sweeney has received support from DynamiCare Health through her faculty position at Johns Hopkins University School of Medicine. Dr A.F. Holtyn has received support from DynamiCare Health and Pear Therapeutics through her faculty position at Johns Hopkins University School of Medicine. Dr M.L. Stitzer has served as consultant to DynamiCare Health. Dr D.R. Gastfriend is co-founder and Chief Medical Officer of DynamiCare Health.

Références

J Subst Abuse Treat. 2021 May;124:108226
pubmed: 33303253
Alcohol Clin Exp Res. 2015 Apr;39(4):743-51
pubmed: 25833033
Drug Alcohol Depend. 2021 Aug 1;225:108786
pubmed: 34087746
Drug Alcohol Depend. 2022 Mar 1;232:109311
pubmed: 35123362
J Med Internet Res. 2016 Mar 23;18(3):e71
pubmed: 27009465
J Med Internet Res. 2020 Nov 24;22(11):e17156
pubmed: 33231555
JAMA. 2020 Jun 16;323(23):2375-2376
pubmed: 32421170
Drug Alcohol Depend. 2017 Sep 1;178:571-578
pubmed: 28750345
Prev Med. 2020 Nov;140:106201
pubmed: 32652133
JMIR Ment Health. 2020 Oct 6;7(10):e22833
pubmed: 33021488
JMIR Ment Health. 2019 Mar 12;6(3):e12493
pubmed: 30860493
Tob Induc Dis. 2019 Sep 09;17:65
pubmed: 31582954
J Addict Med. 2017 May/Jun;11(3):163-173
pubmed: 28557958
J Addict Med. 2020 Jul/Aug;14(4):319-325
pubmed: 31972762
Subst Abus. 2022;43(1):539-546
pubmed: 34520702
Alcohol Clin Exp Res. 2016 Sep;40(9):1991-2000
pubmed: 27488212
J Telemed Telecare. 2019 Jul;25(6):327-342
pubmed: 29788807
Drug Alcohol Depend. 2020 Oct 1;215:108201
pubmed: 32777691
J Subst Abuse Treat. 2021 Feb;121:108197
pubmed: 33357606
J Subst Abuse Treat. 2020 Nov;118:108124
pubmed: 32893047
JAMA Psychiatry. 2014 May;71(5):566-72
pubmed: 24671165
J Consult Clin Psychol. 2013 Oct;81(5):890-900
pubmed: 23875821
J Med Internet Res. 2021 Feb 15;23(2):e25578
pubmed: 33482628
Hosp Pract (1995). 2021 Dec;49(5):348-355
pubmed: 34461801
J Subst Abuse Treat. 2021 Apr;123:108263
pubmed: 33612196
Mayo Clin Proc. 2020 Dec;95(12):2709-2718
pubmed: 33276843
Addiction. 2017 Jun;112(6):1025-1035
pubmed: 28107772
JMIR Mhealth Uhealth. 2019 Apr 22;7(4):e11831
pubmed: 31008713
J Subst Abuse Treat. 2021 Jun;125:108312
pubmed: 34016299
Am J Psychiatry. 2014 Jun;171(6):683-90
pubmed: 24700332
Alcohol Clin Exp Res. 2021 May;45(5):1091-1099
pubmed: 33966283
Drug Alcohol Depend. 2019 Nov 1;204:107592
pubmed: 31586804
J Subst Abuse Treat. 2021 Mar;122:108215
pubmed: 33248863
J Subst Abuse. 1998;10(3):291-308
pubmed: 10689661
J Gen Intern Med. 2022 May;37(7):1610-1618
pubmed: 34159547
Psychiatr Clin North Am. 2022 Mar;45(1):95-107
pubmed: 35219445
Telemed J E Health. 2022 Jun;28(6):761-767
pubmed: 34714172
JAMA Intern Med. 2020 Nov 1;180(11):1472-1480
pubmed: 32955554
Alcohol Clin Exp Res. 2018 Dec;42(12):2423-2431
pubmed: 30335205
Exp Clin Psychopharmacol. 2021 Oct;29(5):555-565
pubmed: 34110885
J Subst Abuse Treat. 2021 Jul;126:108425
pubmed: 34116816
J Subst Abuse Treat. 2021 Jan;120:108188
pubmed: 33298295
JMIR Mhealth Uhealth. 2021 Feb 22;9(2):e23080
pubmed: 33616545
Addict Behav. 2021 Jan;112:106616
pubmed: 32932102
J Subst Abuse Treat. 2019 Jun;101:38-49
pubmed: 31006553
J Appl Behav Anal. 2021 Jan;54(1):38-53
pubmed: 33258134
J Subst Abuse Treat. 2021 May;124:108288
pubmed: 33771285
Alcohol. 2019 Dec;81:131-138
pubmed: 30710610
Front Psychiatry. 2021 Dec 07;12:778992
pubmed: 34950072
Am J Psychiatry. 2014 Apr;171(4):436-44
pubmed: 24577287
J Subst Abuse Treat. 2021 May;124:108283
pubmed: 33771282
Subst Use Misuse. 2019;54(9):1438-1449
pubmed: 30931681
Drug Alcohol Depend. 2021 Oct 1;227:108917
pubmed: 34399136
Addiction. 2019 Nov;114(11):1915-1925
pubmed: 31265747
J Subst Abuse Treat. 2021 May;124:108272
pubmed: 33771276
N Engl J Med. 2016 Dec 22;375(25):2504-2505
pubmed: 28002704
Clin Chem. 2009 Nov;55(11):1910-31
pubmed: 19745062
J Subst Abuse Treat. 2021 Mar;122:108242
pubmed: 33509419
Subst Abuse. 2019 Jul 08;13:1178221819861377
pubmed: 31312084

Auteurs

Mary M Sweeney (MM)

Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.

August F Holtyn (AF)

Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.

Maxine L Stitzer (ML)

Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA; Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.

David R Gastfriend (DR)

DynamiCare Health, 6 Liberty Square, Suite 2102, Boston, MA 02109, USA. Electronic address: drgastfriend@dynamicarehealth.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH